Testing Allows Researchers to Determine Possibility of Drug-Drug Interactions Before Clinical Trials State College, PA (19 June 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay to their portfolio. This kit expands INDIGO’s
By combining the advantages of upcyte hepatocytes with INDIGO’s industry-leading platform and science, the new hepatotoxicty assay kit helps researchers get the information they need to confidently advance their discovery processes.
View Full Size Research conducted by: Samaar Maalouf (1), Bruce Sherf(1), & Jack Vanden Huevel (1,2) (1) INDIGO Biosciences, Inc., 1981 Pine Hall Road, State College, PA, USA (2) Center for Molecular Toxicology and Carcinogenesis, 325 Life Sciences Building, Penn State University, University Park, PA 16802, USA Date of publication: 2017
In Vitro Toxicology Platform Product Family Product Number Product Description Technical Manual In Vitro Toxicology ULC1003-48 in vitro Screening for Drug-Induced Hepatotoxicty, 2x 48 Assays in 96-well format Technical Manual
In vitro toxicology platform provides predictive model of liver toxicity. Aims to reduce the high rates of drug-induced liver damage State College, PA (May 4, 2016) INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has completed development of an in vitro toxicology platform, meeting the demand for predictive liver toxicity models. INDIGO’s in
ABSTRACT Cytochrome P450 CYP26 enzymes are responsible for all-trans-retinoic acid (atRA) clearance. Inhibition of CYP26 enzymes will increase endogenous atRA concentrations and is an attractive therapeutic target. However, the selectivity and potency of the existing atRA metabolism inhibitors towards CYP26A1 and CYP26B1 is unknown, and no selective CYP26A1 or CYP26B1 inhibitors have been developed. Here